2.12
price down icon5.78%   -0.13
pre-market  プレマーケット:  2.15   0.03   +1.42%
loading
前日終値:
$2.25
開ける:
$2.25
24時間の取引高:
171.33K
Relative Volume:
0.92
時価総額:
$30.41M
収益:
-
当期純損益:
$-26.26M
株価収益率:
-0.3102
EPS:
-6.8353
ネットキャッシュフロー:
$-26.82M
1週間 パフォーマンス:
+35.90%
1か月 パフォーマンス:
-6.19%
6か月 パフォーマンス:
-63.61%
1年 パフォーマンス:
-43.16%
1日の値動き範囲:
Value
$2.10
$2.25
1週間の範囲:
Value
$1.55
$2.30
52週間の値動き範囲:
Value
$1.20
$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
名前
Tempest Therapeutics Inc
Name
セクター
Healthcare (1112)
Name
電話
415-798-8589
Name
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Name
職員
4
Name
Twitter
Name
次回の収益日
2026-03-26
Name
最新のSEC提出書
Name
TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TPST icon
TPST
Tempest Therapeutics Inc
2.12 32.27M 0 -26.26M -26.82M -6.8353
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-22 アップグレード H.C. Wainwright Neutral → Buy
2025-04-10 ダウングレード H.C. Wainwright Buy → Neutral
2025-04-10 ダウングレード Scotiabank Sector Outperform → Sector Perform
2024-03-14 開始されました Scotiabank Sector Outperform
2024-02-08 開始されました Jefferies Buy

Tempest Therapeutics Inc (TPST) 最新ニュース

pulisher
Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Bitget

Apr 14, 2026
pulisher
Apr 14, 2026

Tempest Therapeutics names Andrew Fang head of business development - Investing.com

Apr 14, 2026
pulisher
Apr 14, 2026

Tempest Therapeutics names Andrew Fang head of business development By Investing.com - Investing.com South Africa

Apr 14, 2026
pulisher
Apr 14, 2026

Tempest brings in China dealmaker for Phase 3-ready cancer drug - Stock Titan

Apr 14, 2026
pulisher
Apr 13, 2026

Tempest Therapeutics(TPST) Stock Options Chain | Quotes & News - Moomoo

Apr 13, 2026
pulisher
Apr 12, 2026

Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN

Apr 12, 2026
pulisher
Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan

Apr 10, 2026
pulisher
Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan

Apr 10, 2026
pulisher
Apr 10, 2026

Buyout Rumor: What is Stran Company Incs revenue forecast2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn

Apr 10, 2026
pulisher
Apr 10, 2026

New Strong Buy Stocks for April 10th - The Globe and Mail

Apr 10, 2026
pulisher
Apr 10, 2026

[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

Apr 10, 2026
pulisher
Apr 08, 2026

TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill

Apr 08, 2026
pulisher
Apr 03, 2026

Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors - marketscreener.com

Apr 03, 2026
pulisher
Apr 02, 2026

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Versant funds report lower Tempest Therapeutics (TPST) ownership levels - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants. - Bitget

Apr 02, 2026
pulisher
Apr 02, 2026

According to a filing submitted to the US Securities and Exchange Commission (SEC), Tempest Therapeutics Inc. will not receive any proceeds from the sale of the company's shares by selling shareholders. - Bitget

Apr 02, 2026
pulisher
Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail

Apr 01, 2026
pulisher
Mar 31, 2026

H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $11 - moomoo.com

Mar 31, 2026
pulisher
Mar 31, 2026

TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView — Track All Markets

Mar 31, 2026
pulisher
Mar 30, 2026

According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock. - Bitget

Mar 30, 2026
pulisher
Mar 30, 2026

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update - bitget.com

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest reports year end 2025 financial results and provides business update - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics 2026 10-K: Pipeline Overview, CAR-T & Small Molecule Oncology Strategies, Key Partnerships, and Competitive Position - Minichart

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics 2025 Loss/Shr $6.33 >TPST - Moomoo

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics 10-K: Net loss $26.3M, EPS $(6.33) - TradingView

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics (NASDAQ: TPST) advances dual CAR-T and liver cancer drug strategy - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics (NASDAQ: TPST) details 2025 loss and CAR-T pipeline gains - Stock Titan

Mar 30, 2026
pulisher
Mar 29, 2026

Tempest Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 29, 2026
pulisher
Mar 27, 2026

TPST Should I Buy - Intellectia AI

Mar 27, 2026
pulisher
Mar 25, 2026

Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k - Investing.com Australia

Mar 25, 2026
pulisher
Mar 25, 2026

Tempest Therapeutics Insider Bought Shares Worth $500,001, According to a Recent SEC Filing - Moomoo

Mar 25, 2026
pulisher
Mar 25, 2026

Matthew Angel’s 37.4% Tempest (NASDAQ: TPST) stake tied to asset deal, private placement - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

TPST SEC FilingsTempest Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 25, 2026
pulisher
Mar 25, 2026

Downgrade Watch: Can Tempest Therapeutics Inc reach all time highs this yearRate Hike & Daily Profit Focused Screening - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 25, 2026

Aug Macro: Will Tempest Therapeutics Inc stock recover after earningsMarket Trend Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 25, 2026

TPST Q4'25 Earnings: revenue estimate is 0 USD - TradingView — Track All Markets

Mar 25, 2026
pulisher
Mar 25, 2026

Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k By Investing.com - Investing.com South Africa

Mar 25, 2026
pulisher
Mar 25, 2026

Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday - Defense World

Mar 25, 2026
pulisher
Mar 24, 2026

Tempest Therapeutics Announces $2 Million Private Placement and Securities Purchase Agreement with Institutional and Strategic Investors - Minichart

Mar 24, 2026
pulisher
Mar 24, 2026

Tempest Therapeutics raises $2 million in private placement By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 23, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 23, 2026
pulisher
Mar 23, 2026

Tempest Therapeutics Announces Private Placement Financing Agreement - tipranks.com

Mar 23, 2026
pulisher
Mar 23, 2026

Tempest Therapeutics raises $2 million in private placement - Investing.com

Mar 23, 2026
pulisher
Mar 23, 2026

Tempest Therapeutics Raises $2.0 Million in Private Placement With Warrants Priced at $2.16 - TradingView

Mar 23, 2026

Tempest Therapeutics Inc (TPST) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
大文字化:     |  ボリューム (24 時間):